Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James M Ford

Showing results (21-30 of 207) with videos related to

Pageof 21
Sort By:
JAMA Oncology|May 19, 2022
A Novel Framework for the Next Generation of Precision Oncology TargetsChristopher T Chen, James M Ford
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Family history as a positive prognostic factor in gastric cancerLincoln D Nadauld, James M Ford
Clinical Breast Cancer|July 1, 2010
Novel treatment approaches for triple-negative breast cancerMelinda L Telli, James M Ford
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Molecular profiling of gastric cancer: toward personalized cancer medicineLincoln D Nadauld, James M Ford
Clinical Advances in Hematology & Oncology : H&O|December 16, 2010
PARP inhibitors in breast cancerMelinda L Telli, James M Ford
Journal of Molecular Medicine (Berlin, Germany)|September 19, 2003
BRCA1 and p53: compensatory roles in DNA repairAnne-Renee Hartman, James M Ford
JAMA|September 28, 2006
Predicting and preventing hereditary colorectal cancerJames M Ford, Alice S Whittemore
Cancer Research|August 28, 2010
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatinKedar Hastak, Elizabeth Alli, James M Ford
Scientific Reports|October 21, 2025
PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cellsSamyuktha Suresh, Lisa McPherson, James M Ford
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2020
Statistical Methods in Precision OncologyYing Lu, J Jack Lee, James M Ford
Pageof 21

Showing results (21-30 of 207) with videos related to

Sort By:
Pageof 21
JAMA Oncology|May 19, 2022
A Novel Framework for the Next Generation of Precision Oncology TargetsChristopher T Chen, James M Ford
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Family history as a positive prognostic factor in gastric cancerLincoln D Nadauld, James M Ford
Clinical Breast Cancer|July 1, 2010
Novel treatment approaches for triple-negative breast cancerMelinda L Telli, James M Ford
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Molecular profiling of gastric cancer: toward personalized cancer medicineLincoln D Nadauld, James M Ford
Clinical Advances in Hematology & Oncology : H&O|December 16, 2010
PARP inhibitors in breast cancerMelinda L Telli, James M Ford
Journal of Molecular Medicine (Berlin, Germany)|September 19, 2003
BRCA1 and p53: compensatory roles in DNA repairAnne-Renee Hartman, James M Ford
JAMA|September 28, 2006
Predicting and preventing hereditary colorectal cancerJames M Ford, Alice S Whittemore
Cancer Research|August 28, 2010
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatinKedar Hastak, Elizabeth Alli, James M Ford
Scientific Reports|October 21, 2025
PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cellsSamyuktha Suresh, Lisa McPherson, James M Ford
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2020
Statistical Methods in Precision OncologyYing Lu, J Jack Lee, James M Ford
Pageof 21